Kenvue Inc. IPO Research Information

Kenvue Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Kenvue Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Kenvue Inc.	KVUE - NYSE	$20.00-$23.00	$22.00	$25.53	172.8 million	5/4/2023
Underwriter(s): Goldman Sachs, JP Morgan, BofA Securities, Citigroup, Deutsche Bank, BNP PARIBAS, HSBC, RBC Capital Markets, UBS Investment Bank
Co-Manager(s): BBVA, ING, IMI - Intesa San Paolo, Santander, UniCredit Capital Markets, Academy Securities, Independence Point Securities, Ramirez & Co., R. Seelaus & Co., Siebert Williams Shank
Industry: Health Care
Filing(s): Filed 2023-01-04 Terms Added 2023-04-24

Kenvue Inc. Quote & Chart - Click for current quote - KVUE

About Kenvue Inc. (adapted from Kenvue Inc. prospectus):
They are the world’s largest pure-play consumer health company by revenue with $15.1 billion in net sales in 2021.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "KVUE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.